ASN Press Releases: 2024 Archives
Latest Release: Trial Assesses Antibody Therapy for Chronic Active Antibody-Mediated Kidney Transplant Rejection
Saturday, October 26, 2024
Chronic active antibody-mediated rejection (caAMR) is a common cause of allograft loss after transplantation, with no approved therapies. Clazakizumab, a monoclonal antibody that targets the inflammatory cytokine interleukin-6 (IL-6), stabilized kidney transplant recipients' kidney function in a phase 2 trial. Investigators now have data from a phase 3 trial with clazakizumab. The findings from the Phase 3 IMAGINE trial, the largest placebo-controlled study in kidney transplant recipients with caAMR, will be presented at ASN Kidney Week 2024 October 23– 27.
Subscribe to ASN Press Releases
Stay on top of the latest happenings with the Society and in the nephrology world by subscribing to the ASN Press Release RSS Feed.
Latest Release: Researchers Test Imlifidase Enzyme Versus Plasma Exchange in Removing Donor-Specific Antibodies in Kidney Transplant Rejection Trial
Saturday, October 26, 2024
For kidney transplant recipients experiencing antibody-mediated rejection, the current standard of care involves removing donor-specific antibodies (DSAs) through plasmapheresis (PLEX)—a procedure that removes antibodies from the plasma portion of the blood. Results from a recent clinical trial reveal that an investigational drug called imlifidase, which cleaves and inactivates the type of antibodies that include DSAs, is more effective than PLEX. The research will be presented at ASN Kidney Week 2024 October 23–27.
Subscribe to ASN Press Releases
Stay on top of the latest happenings with the Society and in the nephrology world by subscribing to the ASN Press Release RSS Feed.
Latest Release: Preclinical Studies Test Novel Gene Therapy for Treating IgA Nephropathy
Saturday, October 26, 2024
IgA nephropathy is an autoimmune kidney disease, and complement, a component of the innate immune system, plays a role in the condition's pathogenesis. Investigators have developed and tested a novel gene therapy that enters kidney cells and enables them to block complement activation. The research will be presented at ASN Kidney Week 2024 October 23– 27.
Subscribe to ASN Press Releases
Stay on top of the latest happenings with the Society and in the nephrology world by subscribing to the ASN Press Release RSS Feed.
More Press Releases
- Researchers Test Imlifidase Enzyme Versus Plasma Exchange in Removing Donor-Specific Antibodies in Kidney Transplant Rejection Trial
For kidney transplant recipients experiencing antibody-mediated rejection, the current standard of care involves removing donor-specific antibodies (DSAs) through plasmapheresis (PLEX)—a procedure that removes antibodies from the plasma portion of the blood. Results from a recent clinical trial reveal that an investigational drug called imlifidase, which cleaves and inactivates the type of antibodies that include DSAs, is more effective than PLEX. The research will be presented at ASN Kidney Week 2024 October 23–27.
Saturday, October 26, 2024 - Preclinical Studies Test Novel Gene Therapy for Treating IgA Nephropathy
IgA nephropathy is an autoimmune kidney disease, and complement, a component of the innate immune system, plays a role in the condition's pathogenesis. Investigators have developed and tested a novel gene therapy that enters kidney cells and enables them to block complement activation. The research will be presented at ASN Kidney Week 2024 October 23– 27.
Saturday, October 26, 2024 - High-Impact Clinical Trials Generate Promising Results for Improving Kidney Health: Part 2
The results of numerous high-impact phase 3 clinical trials that could affect kidney-related medical care will be presented in-person at ASN Kidney Week 2024 October 23–27.
Saturday, October 26, 2024 - Global, National, and Regional Trends in the Burden of Chronic Kidney Disease among Women
A recent analysis reveals that the number of chronic kidney disease (CKD) cases in women around the globe nearly tripled in the past three decades. Also, type 2 diabetes and hypertension were the leading causes of CKD-related deaths in women. The research will be presented at ASN Kidney Week 2024 October 23– 27.
Friday, October 25, 2024 - Do Certain Diabetes Drugs Increase the Risk of Acute Kidney Injury in Patients Taking Anti-Cancer Therapies?
Glucagon-like peptide-1-receptor agonists (GLP-1RA) are medications that are increasingly prescribed for patients with type 2 diabetes and congestive heart failure. Reports of GLP-1RA–associated acute kidney injury (AKI) have emerged, but the risk of GLP-1RA–associated AKI among patients on anti-cancer drugs is unclear. Surprisingly, new research suggests that taking GLP-1RA is not associated with an increased risk of AKI in patients receiving anti-cancer therapies. The findings will be presented at ASN Kidney Week 2024 October 23– 27.
Friday, October 25, 2024 - How the Novel Antibody Felzartamab Impacts IgA Nephropathy
IgA nephropathy (IgAN) is an autoimmune kidney disease driven by immune cells that express a protein called CD38 on their surface. A recent Phase 2 trial revealed that felzartamab, an investigational anti-CD38 monoclonal antibody, helps reduce proteinuria and maintain patients' kidney function. Investigators evaluated the molecular mechanisms underlying felzartamab's potential efficacy in IgAN. The findings will be presented at ASN Kidney Week 2024 October 23–27.
Friday, October 25, 2024 - Heart and Kidney Outcomes After Canagliflozin Treatment in Older Adults
Sodium-glucose co-transporter 2 (SGLT2) inhibitors reduce the risk of cardiovascular and kidney outcomes in patients with type 2 diabetes, but it is unclear whether their effects differ based on patients' age. A recent analysis of clinical trial data reveals that the SGLT2 inhibitor canagliflozin benefited patients across all age categories. The findings will be presented at ASN Kidney Week 2024 October 23 – 27.
Friday, October 25, 2024 - Researchers Integrate Multiple Protein Markers to Predict Health Outcomes in Individuals with Chronic Kidney Disease
Prior efforts to identify novel kidney biomarkers as risk factors for chronic kidney disease (CKD) progression have typically evaluated proteins individually, which limits their prognostic power. The National Institute of Diabetes and Digestive and Kidney Diseases' (NIDDK's) CKD Biomarkers Consortium of investigators recently developed and tested novel dimensions of kidney health by combining a set of 17 urine and plasma biomarkers that had been individually associated with CKD progression. The research will be presented at ASN Kidney Week 2024 October 23– 27.
Friday, October 25, 2024 - High-Impact Clinical Trials Generate Promising Results for Improving Kidney Health: Part 1
The results of numerous high-impact phase 3 clinical trials that could affect kidney-related medical care will be presented in-person at ASN Kidney Week 2024 October 23–27.
Friday, October 25, 2024 - The Clinical Significance of Microvascular Inflammation after Kidney Transplantation
Investigators recently uncovered key insights into newly defined rejection entities in kidney transplantation that may offer improved patient risk categorization post-transplant. The research will be presented at ASN Kidney Week 2024 October 23– 27.
Thursday, October 24, 2024 - AMERICAN SOCIETY OF NEPHROLOGY LAUNCHES THE GLOMERULAR DISEASES COLLABORATIVE (GD-C) TO ADDRESS GAPS IN KNOWLEDGE AND BARRIERS IN THE CARE OF PEOPLE WITH GLOMERULAR DISEASES
Washington, DC (October 2, 2024) — Chronic kidney disease is a progressive condition that affects more than 10% of the general population worldwide, amounting to 800 million individuals.1 Glomerular diseases (GD), excluding diabetic nephropathy, account for approximately 25% of the cases of kidney diseases worldwide.2 Given the magnitude of long-term morbidity from GD— particularly the frequent manifestation in younger patients—diagnosing it efficiently and optimizing management to control diseases and prevent progressive kidney diseases is paramount.2,3
Wednesday, October 2, 2024 - AMERICAN SOCIETY OF NEPHROLOGY RELEASES KIDNEY HEALTH GUIDANCE ON THE MANAGEMENT OF OBESITY IN PERSONS WITH KIDNEY DISEASES
To promote high-quality, person-directed care across the spectrum of kidney health and diseases, the American Society of Nephrology (ASN) is releasing its inaugural Kidney Health Guidance (KHG) on the Management of Obesity in Persons Living with Kidney Diseases in the Journal of the American Society of Nephrology (JASN) on September 18, 2024. The guidance provides kidney health professionals and kidney care teams with knowledge on the existing tools for obesity management and guidance on implementation of these tools within clinical practice based on best available evidence and expert opinion.
Wednesday, September 18, 2024 - New Policy Will Remove Race, Improve Equity in Transplantation
The following is a joint Statement from the National Kidney Foundation (NKF) and American Society of Nephrology (ASN) on the Organ Procurement and Transplantation Network (OPTN) plans to remove the African American/Black race coefficient from the Kidney Donor Profile Index (KDPI) calculation.
Monday, July 8, 2024 - KIDNEYCURE ANNOUNCES 2024 GRANT RECIPIENTS
• KidneyCure (the ASN Foundation) is honored to continue its support of investigators committed to advancing kidney health. Building on decades of success, KidneyCure makes it possible to improve knowledge and treatment by identifying and funding high-impact projects. • Investigators funded by KidneyCure are making a difference in key areas that impact care for millions. KidneyCure is proud to support excellence and innovation, and to extend the advances that the foundation has propelled since its inception.
Thursday, June 27, 2024 - AMERICAN SOCIETY OF NEPHROLOGY COMMENDS THE HOUSE ENERGY AND COMMERCE COMMITTEE FOR ADVANCING THE HONOR OUR LIVING DONORS (HOLD) ACT (H.R. 6020)
The American Society of Nephrology (ASN) applauds the House Energy and Commerce Committee for unanimously passing the Honor Our Living Donors Act (H.R. 6020), to ensure that only the income of a living donor can be considered when determining eligibility for federal financial assistance provided to living donors. The bipartisan legislation now awaits action on the House floor and in the Senate. ASN will continue to advocate for passage of the HOLD Act and on behalf of policies to make living donations financially neutral.
Wednesday, June 12, 2024 - INCREASING ORGAN TRANSPLANT ACCESS (IOTA) MODEL ANNOUNCED TO INCREASE PATIENT ACCESS TO KIDNEY TRANSPLANTATION
The long-awaited Increasing Organ Transplant Access (IOTA) Model was released yesterday by the Center for Medicare and Medicaid Innovation (CMMI) focusing on increasing patients' access to kidney transplantation across the United States. The 6-year model will randomize an estimated 90 transplant centers of the 231 facilities actively performing kidney transplants nationwide. It "aims to increase access to kidney transplants for all people living with end-stage renal disease (ESRD), improve the quality of care for people seeking kidney transplants, reduce disparities among individuals undergoing the process to receive a kidney transplant, and increase the efficiency and capability of transplant hospitals selected to participate."
Thursday, May 9, 2024 - CYNTHIA DELGADO AND NEIL POWE NAMED TO TIME100 HEALTH LIST FOR FIGHTING KIDNEY TRANSPLANT BIAS
TIME has included the co-chairs of the National Kidney Foundation (NKF)/ American Society of Nephrology (ASN) Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Diseases, among its first-ever list of the 100 most influential people in global health. The magazine recognized Cynthia Delgado, MD, FASN and Neil Powe, MD, MPH, MBA for their efforts to correct racial bias in the algorithm used to diagnose kidney diseases, an algorithm that often determines access to a kidney transplant.
Friday, May 3, 2024 - KIDNEY HEALTH INITIATIVE UNVEILS APOL1 ROADMAP TO ADDRESS APOL1 KIDNEY DISEASE
APOL1 Kidney Disease (APOL1 KD) is a genetic condition that affects people who carry a high-risk APOL1 gene variant. Most people with those variants are of African ancestry.
Tuesday, April 23, 2024 - AMERICAN SOCIETY OF NEPHROLOGY CALLS ON CONGRESS TO INCREASE FUNDING FOR THE US TRANSPLANT SYSTEM
Today, leaders from the American Society of Nephrology (ASN) will meet with their congressional delegations and call for their support of an $8 million increase for the Health Resources and Services Administration (HRSA) Organ Transplantation Program in FY 25 This funding, totaling $67 million, will be used to continue Congress' commitment to people seeking a transplant and will implement reforms to modernize the transplant system and make transplant care more accessible.
Thursday, April 18, 2024 - International Consensus Statement Published in Nature Reviews Nephrology Calls for Urgent Action to Address Chronic Kidney Disease on the Global Public Health Agenda
On April 3, 2024, Nature Reviews Nephrology published a landmark international consensus statement titled "Chronic Kidney Disease and the Global Public Health Agenda: An International Consensus." Authored by a coalition of leading experts, stakeholders, and nephrology societies, the publication highlights critical policy, advocacy, and implementation needs to alleviate the growing burden of kidney disease worldwide.
Thursday, April 4, 2024 - AMERICAN SOCIETY OF NEPHROLOGY CELEBRATES TRANSFORMATIONAL TRANSPLANT FUNDING
Delivering on its commitment to increase Americans' access to kidney transplant by improving the transparency and efficiency of our nation's transplant network, Congress this week approved a much-needed $23 million federal funding increase in fiscal year (FY) 2024 for the Health Resources and Services Administration (HRSA), the agency responsible for overseeing the Organ Procurement and Transplantation Network (OPTN). This funding follows significant reforms passed by Congress in 2023 by means of the Securing the US Organ Procurement and Transplantation Network (OPTN) Act, which are being implemented by HRSA through the OPTN Modernization Initiative.
Sunday, March 24, 2024 - AMERICAN SOCIETY OF NEPHROLOGY AND HOME DIALYSIS UNIVERSITY EXPAND COLLABORATION TO ENHANCE HOME THERAPIES EDUCATION FOR NEPHROLOGY FELLOWS
After a Successful Launch of the ASN HDU Home Dialysis Scholarship Program in 2023, ASN and HDU Will Continue the Program and Increase the Number of Scholarships Awarded to Fellows in 2024.
Monday, March 18, 2024 - AMERICAN SOCIETY OF NEPHROLOGY APPLAUDS THE WAYS AND MEANS COMMITTEE FOR ADVANCING THE KIDNEY PATIENT ACT (HR 5074)
The American Society of Nephrology (ASN) commends congressional leaders on the House Ways and Means committee for advancing the Kidney PATIENT Act, bipartisan legislation to maintain patient access to oral-only medications by retaining coverage through Medicare Part D.
Thursday, March 7, 2024 - AMERICAN SOCIETY OF NEPHROLOGY COMMENDS CONGRESS FOR HIGHLIGHTING THE HONOR OUR LIVING DONORS ACT (H.R. 6020)
At a hearing today focused on supporting patients with rare diseases, the House Energy and Commerce Health Subcommittee will consider Honor Our Living Donors Act (H.R. 6020), legislation to improve support for living organ donors.
Thursday, February 29, 2024